OrganiGram
VC Fund
Moncton, Canada
OrganiGram is a producer and distributor of medical and recreational cannabis. They are dedicated to consistently providing clients with the highest grade medicine and service. Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international businesspartnerships to extend the Company’s global footprint.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 92%
Last updated:
For AI agents: llms.txt
Industries OrganiGram invests in
Stages OrganiGram invests in
Countries OrganiGram invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Convertible Note
- $1M–$12M
Investment Focus
Industry
- Cannabis 4 (33%)
- Biotechnology 3 (25%)
- Medical 2 (17%)
- Manufacturing 2 (17%)
- AgTech 1 (8%)
Stage
- Convertible Note 3 (25%)
- Series B 1 (8%)
- Debt Financing 1 (8%)
- Corporate Round 1 (8%)
- Secondary Market 1 (8%)
Country
- Canada 2 (17%)
- United States 2 (17%)
- Germany 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Beena Goldenberg
Chief Executive Officer
|
Chief Executive Officer | Total investments: 1 | Find email | |
Greg Engel
CEO
|
CEO | Total investments: 0 | Find email | |
Greg Guyatt
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
Jim Laffoley
President & Founder
|
President & Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Phylos is an agricultural genomics company using modern molecular genetics and computational biology to power the next generation of hemp and cannabis. Phylos provides breeding and R&D services to global partners and offers a suite of genetic services and testing solutions. We remain committed to a sustainable cannabis industry and to thepreservation of genetic diversity through the Phylos Galaxy and publicly accessible data, like the Open Cannabis Project.We are a new generation of plant scientists, transforming the hemp and cannabis industries with unparalleled data, technology, and expertise. Phylos is strategically positioned to provide cultivators with the tools to understand the breadth of genetics in their catalog, evaluate the development of additional varieties, and drive business growth. | $3M / Convertible Note / Dec 31, 2025 | ||
| Phylos is an agricultural genomics company using modern molecular genetics and computational biology to power the next generation of hemp and cannabis. Phylos provides breeding and R&D services to global partners and offers a suite of genetic services and testing solutions. We remain committed to a sustainable cannabis industry and to thepreservation of genetic diversity through the Phylos Galaxy and publicly accessible data, like the Open Cannabis Project.We are a new generation of plant scientists, transforming the hemp and cannabis industries with unparalleled data, technology, and expertise. Phylos is strategically positioned to provide cultivators with the tools to understand the breadth of genetics in their catalog, evaluate the development of additional varieties, and drive business growth. | $1M / Convertible Note / Jul 24, 2024 | ||
| Sanity Group is a holistic European Cannabis company focusing on health, wellbeing, and scientific research. To utilize the full potential of its health benefits, Sanity Group is investing in fundamental research of the cannabis plant and its active ingredients as well as in specific areas of application.It was founded in 2018 and headquarteredin Berlin, Germany. | $12.3M / Convertible Note / Jun 25, 2024 | ||
| Sanity Group is a holistic European Cannabis company focusing on health, wellbeing, and scientific research. To utilize the full potential of its health benefits, Sanity Group is investing in fundamental research of the cannabis plant and its active ingredients as well as in specific areas of application.It was founded in 2018 and headquarteredin Berlin, Germany. | $2.7M / Secondary Market / Jun 25, 2024 | ||
| Open Book Extracts is a cGMP certified, vertically integrated grower, processor, and manufacturer of premium plant-based products. With control of the entire supply chain, a state-of-the-art extraction campus near North Carolina’s Research Triangle, proprietary refinement and conversion methods backed by a growing IP portfolio, and a team of Ph.D.chemists and seasoned business leaders, OBX is the trusted partner for global brands seeking to enter the marketplace. OBX Asia, with its headquarters in Hong Kong, provides strategic guidance and on-the-ground support for our Asia customers.OBX’s cGMP-certified productions operations are led by a seasoned science team, including a Ph.D. food scientist from Cornell, a Ph.D. organic chemist from the University of Nevada, and two masters chemists with pharmaceutical backgrounds, including a quality control director who joined OBX after a 15-year career as an analytical chemist at GlaxoSmithKline. OBX offers one of the largest portfolios of cannabinoid isolates at 99%+ purity, including CBD, CBG, CBN, CBC, and THCV, as well as formulation services and turnkey, finished good manufacturing including edibles, soft gels, tablets, tinctures, pet products, and topical products. | $2M / Convertible Note / Mar 26, 2024 | ||
| Phylos is an agricultural genomics company using modern molecular genetics and computational biology to power the next generation of hemp and cannabis. Phylos provides breeding and R&D services to global partners and offers a suite of genetic services and testing solutions. We remain committed to a sustainable cannabis industry and to thepreservation of genetic diversity through the Phylos Galaxy and publicly accessible data, like the Open Cannabis Project.We are a new generation of plant scientists, transforming the hemp and cannabis industries with unparalleled data, technology, and expertise. Phylos is strategically positioned to provide cultivators with the tools to understand the breadth of genetics in their catalog, evaluate the development of additional varieties, and drive business growth. | $2.8M / Convertible Note / Nov 28, 2023 | ||
| Phylos is an agricultural genomics company using modern molecular genetics and computational biology to power the next generation of hemp and cannabis. Phylos provides breeding and R&D services to global partners and offers a suite of genetic services and testing solutions. We remain committed to a sustainable cannabis industry and to thepreservation of genetic diversity through the Phylos Galaxy and publicly accessible data, like the Open Cannabis Project.We are a new generation of plant scientists, transforming the hemp and cannabis industries with unparalleled data, technology, and expertise. Phylos is strategically positioned to provide cultivators with the tools to understand the breadth of genetics in their catalog, evaluate the development of additional varieties, and drive business growth. | $3.3M / Convertible Note / May 25, 2023 | ||
| A global leader in vaporizing hardware and product design, they are committed to shaping the industry by developing innovative technologies. At Green Tank Technologies, they know that producers and extractors spend years and tons of money developing their quality bud and oil. They set out on a mission to provide quality devices that deliver fullflavor and the ultimate user experience. Green Tank designs, develops, and produces industry leading quality vaporization hardware with True-Taste Ceramic Core Technology for full flavor and maximum terpene profiles. | $14.5M / Series B / Mar 31, 2023 | ||
| We’re a bioengineering company that's reducing the massive environmental footprint of the CBD market through precision fermentation. And our technology never touches a plant. CBD is a global $12Bn consumer market and Hyasynth's precision fermentation platform eliminates wasteful plant cultivation and decreases the carbon impact by morethan 97%. Hyasynth is the world's only bioengineering company with a scalable, fermentation process for CBD that is cost-efficient and regulatory-compliant. | $1.9M / Debt Financing / Dec 22, 2021 | ||
| We’re a bioengineering company that's reducing the massive environmental footprint of the CBD market through precision fermentation. And our technology never touches a plant. CBD is a global $12Bn consumer market and Hyasynth's precision fermentation platform eliminates wasteful plant cultivation and decreases the carbon impact by morethan 97%. Hyasynth is the world's only bioengineering company with a scalable, fermentation process for CBD that is cost-efficient and regulatory-compliant. | $1.9M / Corporate Round / Oct 23, 2020 | ||
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does OrganiGram invest in?
OrganiGram invests primarily in Cannabis, Biotechnology and Medical startups, most often at Convertible Note and Series B stage. Most of the 12 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is OrganiGram's check size?
OrganiGram typically joins rounds of $1M–$12M at Convertible Note. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds OrganiGram participates in.
How do I contact OrganiGram?
Public channels for OrganiGram include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at OrganiGram?
The team at OrganiGram includes Beena Goldenberg (Chief Executive Officer), Greg Engel (CEO) and Greg Guyatt (Chief Financial Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
